The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Just twigged our closing SP 685 is half the target price reiterated by Numis today of 1365
Porky - everyone has read the broker note & the SP is the same as start of the day, starting with a 6.
The economic potential ought to be valued more in line with the broker note & my point is about how that is brought about. We know other companies are more presentation than delivery, this one has had great/world class delivery through a period that it needed to be focused but that has made the SP swing in the wind. There could be less lottery in the swings & it would make the investment more attractive than requiring faith that the market is wrong.
@donnotrader
' Well positioned to grow the business in line with our strategy of delivering long term value to our shareholders'.
Ad4 if that was directed at me, I can assure you that my views are based on my knowledge of the RNS(s) throughout the last year and their deleterious impact on share price because, wonderful as they have been for strategic content, they have been tone deaf to how they will be received by the market.
What concerns me with some of the posters here - after an excellent RNS today with updates on where the business is with bringing their products to market (World Leading in many cases) yes granted at this stage no financials - you wouldn't have to be an idiot to know what financials could be in reach and had you taken the time to read the brokers report would give you an indication even without some of the contracts what the forecast is.
However the most annoying for me is that some posters even want to re-write the RNS as they don't feel it reads well enough - God get a grip!
I hope too goodness that whatever business you are in it is operating Par Excel lance! Mind perhaps it's not else otherwise you wouldn't be invested here too make your fortune!
Please as said so many times on here "Get Real"
ROFL, ROFL, ROFL..
troublesome it is certainly better than stating 'it is difficult to provide a clear forecast on the financial performance for full year 2021. '
Can you do an audio version of that, can't be bothered to read it, lol
Why oh Why am i returning to this BB with so much diss-information....
Read the bloody broker notes;
https://novacyt.com/wp-content/uploads/2021/02/SP-Angel-Update-04.02.2021.pdf
The business is on track to deliver currently 271m of sales 173m EBITDA and cash at bank for acquisitions of 278m IN THE CURRENT YEAR - they can't be any bloody clearer!!!!!!
This is without ANY large contract orders, ABY sales from new product lines, ANY revenues from Acquisitions
I can only assume that there is some specific agenda in posters visiting this board without doing ANY research and trying to convince Retail investors the business has no forward direction and its a waste of time. It is the only one delivering real results from proven revenues. Its supplying 130 countries, employing 140 odd staff, boots on the ground and securing orders in the USA, has 550 products out there and is leading the WORLD on whole genome sequencing, vital for vaccines.
The RNS this morning
"An international specialist in clinical diagnostics"
"The Company is also continuing to build on its strategy for delivering a sustainable, long-term diagnostics business"
Do some dam Research - Annoyed because its so basic - can't people read what's in front of them anymore????????
@donnotrader
No point in stating the bleeding obvious - Lol
Tks to Larry
https://twitter.com/Larry64450205/status/1364607739536830468
what about - we are confident that these developments will continue to enhance the profitability of the company into 2021 and beyond.
Donno I agree that line was a f*** up but how do you suggest they take it back without giving concrete info, which could only come with confirmation of contracts? Anything else from GM would sound woolly and unconvincing, I think the broker notes being reissued is an attempt to emphasise the estimates they are currently comfortable with
the difficulty is that the company needs to be proactive to overcome the big mistake in the previous RNS.
'it is difficult to provide a clear forecast on the financial performance for full year 2021. '
they had an opportunity today, and did not take it. So much for the new PR!!!
It’s not true that we don’t have any idea at all of future income- unless the company updates us otherwise then the broker notes provide all the forecasts we are going to get...GM will have agreed that they are reasonable assumptions for the analysts to make and given that this will form the basis of ‘expectations in the market’, if something happens to cause much deviation above or below them then an rns would be required to adjust accordingly.
Agree with you mburns70 - Yes, despite being very proactive and qualitative in R&D and Innovation, they must also be a bit more dynamic in managing the market and shareholders value by releasing more quantitative information.
As I've grown older I've realised how difficult it is to please everyone all the time but pi**ing everyone off is a piece of cake.
Today was R and D and I definitely thought it was more rampy as a nod to what has been said. I hear you Try2buylow , let's see if an operational update is forthcoming , perhaps the floodgates have been prised open.
It was a pleasant surprise to find some communication here today, they clearly are showing that they at least hear investors concerns. For me it really still needs numbers, the all important forecasts. I know I've mentioned him before but he's just an example when Martin Sorrel releases an RNS its all numbers numbers numbers and they work. I didn't invest here just because of covid but because I have great faith in the research expertise of Novacyt, there's no doubt they are experts in diagnostics but they are not a private company, the market side and what it expects even demands cannot be ignored as much as they might like to or find an inconvenience. A new sales team is only really starting and that will take a little time and fingers crossed they have taken on good people in this essential role. If they could just get the investment/market aspect under control it would certainly give this the boost it needs. But the research and development aspect is undeniably excellent.
Too many day traders and technical traders in it at the moment, which creates volatility and distracts from fundamentals. How I loath technical trading, even though that's actually part of my own job. Count me among the fundamentalists, always look for true value not a line on a chart.
exactly donn!
Kaeren & so many others here are doing some wonderful spotting what is happening such as the enlightneing post below about involvement with Brazilian National initiatives but. why do they have to do it? what concept should we have of how it supports the P&L this year? Involved with such a forward looking enterprise is fantastic but they could make so much more of their commerciality. We have to guess what'll come out of the black box next
as far as the market is concerned the income for 2021 is still 'uncertain'. in the midst of all the great strategic news, a lost opportunity today give a positive steer.
But it has a huge disadvantage to shareholders in not having visibility of future income.
Contributors comment about SHs being over demanding of updates. A business ought to get on with its activity & this lot have been making world class headway in the heat of battle on the other hand what can any investor tell about income? There would be a basis to estimate in most situations, what we have here is a request for blind faith. No one can tell the outcome of a negotiation and the demand for capacity outside that negotiation is simply unknown. What would the lag be before finding a new customer base? have they got one already? we just can't tell so the market can't know what NCYT may be worth going on information available to PIs without some dark art of divination, like something out of the dark ages, so of course the SP will drift down until an RNS arrives to shed some light. This isn't how a businesses make best use of their access to support.
NCYT is proving that their R&D Department is yielding a practical useful output in an efficient way. This company knows well how to put theory into practice very quickly. Today RNS showed that NCYT can now offer a wide array of in-house sophisticated products . It is also indirectly killing slowly but surely any competition. NCYT has taken a huge advance on others. IMO it will end up taken over probably this year.